Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Cosmo Half-Year Report 2019

share with twitter share with LinkedIn share with facebook
07/30/2019 | 01:05am EDT

Cosmo Half-Year Report 2019

Dublin, Ireland - 30 July 2019 - Cosmo Pharmaceuticals N.V. (SIX: COPN) reports half-year results for the period ended 30 June 2019.

Key Events Half-Year 2019 - Products and Business

  • Revolutionary artificial intelligence product GI Genius for the detection of lesions during colonoscopy unveiled and subsequent worldwide validation deal entered into with Medtronic.
  • Collaboration agreement entered into with Medtronic in the artificial intelligence field for additional indications.
  • Eleview® distribution agreement entered into with Medtronic for USA, China and South America with sales expected to begin in August 2019.
  • Investigational New Drug (IND) for new chemical entity CB-03-10 for new oncologic product accepted by the FDA.
  • ByFavo™ (remimazolam) NDA accepted by the FDA.
  • Aries restructuring completed, savings of c. €20m expected in 2019.
  • Very positive results of Breezula® full phase II clinical trial announced by our associate Cassiopea.
  • Aemcolo™ phase II proof of concept study in IBS-D progressed.
  • Health Canada approved Eleview® which will be commercialised by Pharmascience under the existing licence agreement.
  • GI Genius to start sales in Europe in July 2019 by Medtronic.
  • Aemcolo™ commercial launch to take place end of July 2019 with direct marketing strategy.

Alessandro Della Chà, Chief Executive Officer, said: "In the first half of this year we took a number of key steps. Following the regulatory delay of MB MMX we have reduced our U.S. cost base significantly; announced new interesting product opportunities (GI Genius and CB-03-10); entered into important deals with Medtronic; shifted strategy for our medical devices and for the Aemcolo launch. In doing so, we are not expecting significant impact on financial results this year, but rather to lay a solid foundation for things to come."

"Although our focus is to achieve US approval for GI Genius in H1 2020, sales have already started in Europe; Aemcolo launch in the US is still on track for end of July and Eleview sales in the US will be reinitiated in August by Medtronic," added Mr Della Chà. "As of June 30, the total of cash and investment in funds, market value of our Cassiopea stake and treasury shares is approx. € 539m/CHF 590m, providing ample financing and flexibility to pursue our strategy for growth. We look to the future with optimism. 2020 will be a pivotal year for us, when we expect to return to profitability."

Financial Highlights Half-Year 2019

  • Revenues €21.5m vs €36.7m last year, impacted by the generic competition for Uceris® and Lialda® in 2018 and up-front fees and milestones received in prior year which did not reoccur.
  • Operating costs down 11.8% to €38.7m following cost reductions in our U.S. organisation. ​
  • Operating loss €17.2m vs €7.2m last year​.
  • Net financial expense €2.6m mainly relates to interest on convertible bonds of €4.1m of which cash impact €2.2m. ​
  • Loss for the period €20.8m including share of Cassiopea loss €2.8m, ESOP costs of €3m and €4.1m convertible bond charge of which € 2.2m coupon paid. ​
  • Cash outflow from operations before changes in working capital €11.0m for the period.
  • Cash and investments in funds €324.0m vs €375.8m at FY18 YE (excluding €35.5m treasury shares). ​
  • Cosmo's stake in Cassiopea worth €180m at 30 June 2019.
  • Total assets €594.7m vs €625.7m at FY18 YE.
  • Equity €404.4m vs €444.8m at FY18 YE​.
  • Purchased 212,214 treasury shares in H1 for €17.2m. As at 30 June 2019 total treasury shares held 413,984.

Key figures

EUR 1,000

H1 2019

H1 2018

Income statement

Revenues

21,507

36,660

Other income

277

240

Cost of sales

(11,029)

(10,714)

R&D costs

(7,667)

(4,459)

SG&A costs

(20,289)

(28,938)

Net Operating Expenses

(38,708)

(43,871)

Operating loss

(17,201)

(7,211)

Net finance (expenses) / income

(2,600)

4,823

Share of result of associate

(2,818)

(2,895)

Loss before taxes

(22,619)

(5,283)

Income tax

1,837

(2,506)

Loss for the period

(20,782)

(7,789)

Shares

Weighted average number of shares

14,715,110

15,033,234

Earnings per share (in EUR)

(1.407)

(0.518)

EUR 1,000

30 Jun 19

31 Dec 18

Statement of financial position

Non-current assets

243,103

251,519

Cash and cash equivalents

158,406

210,689

Other current assets

193,222

163,478

Liabilities

190,369

180,832

Equity attributable to owners of the Company

404,362

443,760

Equity ratio (%)

68.0%

71.1%

The Half-Year Report 2019 with further information was published on 30 July 2019, 07:00 am CET, and is available for download at:

http://www.cosmopharmaceuticals.com/investor-relations/financial-reports

Half-Year 2019 Results Conference Call on Tuesday, 30 July 2019, 10:30am CET

Alessandro Della Chà, CEO, Luigi Moro, CSO, Niall Donnelly, CFO will present the half-year results 2019 and will provide an update of Cosmo's activities. The conference call is scheduled to last 30-45 minutes and will be held in English.

Dial-in numbers:

From Continental Europe:

+41 (0)58 310 50 00

From UK:

+44 (0)207 107 06 13

From USA:

+1 (1) 631 570 56 13

The presentation is available for download at:

http://www.cosmopharma.com/ir/presentations.aspx




Provider
Channel
Contact
EQS Group Ltd., Switzerland
switzerland.eqs.com


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
cs.switzerland@eqs.com
+41 41 763 00 50
share with twitter share with LinkedIn share with facebook
Latest news on COSMO PHARMACEUTICALS N.V.
07/30Cosmo Half-Year Report 2020
TE
07/15Cosmo Pharmceuticals assigns US license agreement for BYFAVOTM (remimazolam) ..
TE
07/09COSMO PHARMACEUTICALS N : announces granting of Marketing Authorization in Italy..
AQ
07/08Cosmo Pharmaceuticals announces granting of Marketing Authorization in Italy ..
TE
07/03Acacia Pharma Announces US FDA Approval of BYFAVO for injection for the Induc..
AQ
07/02Cosmo Pharmaceuticals Announces US FDA Approval of BYFAVO™ (remimazolam..
TE
07/01Cosmo Pharmaceuticals Appoints new CSO
TE
06/29COSMO PHARMACEUTICALS N : receives positive EMA CHMP Opinion recommending approv..
AQ
06/26Cosmo receives positive EMA CHMP Opinion recommending approval of Methylene B..
TE
06/24COSMO PHARMACEUTICALS N : announces regulatory approval of GI GENIUS in Israel
AQ
More news
Financials
Sales 2020 52,6 M 62,1 M 62,1 M
Net income 2020 -8,55 M -10,1 M -10,1 M
Net cash 2020 51,0 M 60,2 M 60,2 M
P/E ratio 2020 -122x
Yield 2020 -
Capitalization 1 173 M 1 382 M 1 385 M
EV / Sales 2020 21,3x
EV / Sales 2021 18,2x
Nbr of Employees 261
Free-Float 46,2%
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 92,59 €
Last Close Price 81,11 €
Spread / Highest target 37,2%
Spread / Average Target 14,2%
Spread / Lowest Target -17,0%
EPS Revisions
Managers
NameTitle
Alessandro E. Della Chà Chief Executive Officer & Executive Director
Mauro Severino Ajani Executive Chairman
Giuseppe Cipriano Chief Operating Officer
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Davide Malavasi Director-Qualified Person & Technical
Sector and Competitors
1st jan.Capitalization (M$)
COSMO PHARMACEUTICALS N.V.16.04%1 398
JOHNSON & JOHNSON1.01%387 947
ROCHE HOLDING AG3.31%300 745
PFIZER, INC.-2.12%213 028
MERCK & CO., INC.-9.25%208 339
NOVARTIS AG-15.79%185 171